The Alliance for Regenerative Medicine Announces Election of 2017 ARM Officers, Executive Committee and Board of Directors
(firmenpresse) - WASHINGTON, DC -- (Marketwired) -- 10/11/16 -- The Alliance for Regenerative Medicine (ARM), announced today the election of the 2017 ARM Officers, Executive Committee and Board of Directors.
"ARM leadership reflects the geographical and technological diversity of our membership," said Morrie Ruffin, managing director of ARM. "We welcome these new slates of officers, directors and executive committee members; each has demonstrated direct involvement and active participation in ARM''s activities and has made vital contributions to the advancement of this sector."
ARM Officer terms are typically two years, while the ARM Board of Directors and Executive Committee are held to an annual re-election or rotation process, with nominations and approval by the ARM membership and Board.
ARM 2017 Officers:
Robert Preti - Co-Founder & President, PCT, a Caladrius Company; Senior Vice President, Manufacturing & Technical Operations and Chief Technology Officer, Caladrius Biosciences (ARM Chairman)
Matt Patterson - President & CEO, Audentes Therapeutics (ARM Vice Chairman)
Martha Rook - Head of Gene Editing and Novel Modalities, MilliporeSigma / EMD Millipore (ARM Secretary)
Rahul Aras - Co-Founder, President & CEO, Juventas Therapeutics (ARM Treasurer)
ARM 2017 Executive Committee:
Rahul Aras - Co-Founder, President & CEO, Juventas Therapeutics (also ARM Treasurer)
Eduardo Bravo - Managing Director & CEO, TiGenix
Doug Doerfler - President & CEO, MaxCyte
Karen Kozarsky - President, Vector Partners
Edward Lanphier - Founder & Chairman, Sangamo BioSciences (ARM ex-officio)
Tom Novak - Vice President, Strategic Partnerships, Cellular Dynamics International / FUJIFILM
Matt Patterson - President & CEO, Audentes Therapeutics (also ARM Vice Chairman)
Robert Preti - Co-Founder & President, PCT, a Caladrius Company; Senior Vice President, Manufacturing & Technical Operations and Chief Technology Officer, Caladrius Biosciences (also ARM Chairman)
Martha Rook - Head of Gene Editing and Novel Modalities, MilliporeSigma / EMD Millipore (also ARM Secretary)
Jay Siegel - Chief Biotechnology Officer and Head, Scientific Strategy & Policy, Johnson & Johnson
David Smith - Vice President, Global Business Development, Lonza
Alexander Vos - CEO, PharmaCell
ARM 2017 Board of Directors:
Zami Aberman - Chairman & CEO, Pluristem Therapeutics
Martin Andrews - Senior Vice President, GSK Rare Disease Unit Head, GSK
Rahul Aras - Co-Founder, President & CEO, Juventas Therapeutics (also ARM Treasurer)
Nessan Bermingham - CEO, President & Founder, Intellia Therapeutics
Eduardo Bravo - Managing Director & CEO, TiGenix
Olivier Danos - Senior Vice President, Cell and Gene Therapy, Biogen
Deborah Dean - Executive Vice President and Chief Compliance Officer, MiMedx
Doug Doerfler - President & CEO, MaxCyte
Flagg Flanagan - Chairman & CEO, DiscGenics
Christian Homsy - CEO, Celyad
Andrea Hunt - Vice President, New Products TA Lead Gene Therapy, Neuroscience and Ophthalmology, Shire
Dena Ladd - Executive Director, Missouri Cures
Paul Laikind - President & CEO, ViaCyte
Edward Lanphier - Founder and Chairman, Sangamo BioSciences (ARM ex-officio)
Michael May - CEO, Centre for Commercialization of Regenerative Medicine
Gregory Naeve - Head External R&D Innovation, ImmunoOncology & Rinat Labs, San Francisco Worldwide Research & Development, Pfizer
Tim Oldham - CEO & Executive Director, Cell Therapies Pty Ltd
Matt Patterson - President & CEO, Audentes Therapeutics (also ARM Vice Chairman)
Robert Preti - Co-Founder & President, PCT, a Caladrius Company; Senior Vice President, Manufacturing & Technical Operations and Chief Technology Officer, Caladrius Biosciences (also ARM Chairman)
Byung Geon ("BG") Rhee - President, Green Cross Holdings
Isabelle Riviere - Director, Cell Therapy & Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
Martha Rook - Head of Gene Editing and Novel Modalities, MilliporeSigma / EMD Millipore (also ARM Secretary)
Jay Siegel - Chief Biotechnology Officer and Head, Scientific Strategy & Policy, Johnson & Johnson
Donna Skerrett - Chief Medical Officer, Mesoblast Ltd
David Smith - Vice President, Global Business Development, Lonza
Keith Thompson - CEO, Cell & Gene Therapy Catapult
Phil Vanek - General Manager, Cell Therapy Technologies, GE Healthcare Life Sciences
Alexander Vos - CEO, PharmaCell
Jeffrey Walsh - Chief Financial and Strategy Officer, bluebird bio
Sue Washer - President & CEO, AGTC
Jason Wertheim - Assistant Professor of Surgery - Organ Transplantation, Department of Surgery, Institute for BioNanotechnology in Medicine, Feinberg School of Medicine and Chemistry of Life Processes Institute, Northwestern University
Claudia Zylberberg - Founder & CEO, Akron Biotech
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 250 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit .
The Alliance for Regenerative Medicine
Lyndsey Scull
202 213 7086
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.10.2016 - 08:00 Uhr
Sprache: Deutsch
News-ID 1463024
Anzahl Zeichen: 4675
contact information:
Contact person:
Town:
WASHINGTON, DC
Phone:
Kategorie:
Commercial & Investment Banking
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 260 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"The Alliance for Regenerative Medicine Announces Election of 2017 ARM Officers, Executive Committee and Board of Directors
"
steht unter der journalistisch-redaktionellen Verantwortung von
The Alliance for Regenerative Medicine (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
